Track Chair:
- William Oh, Mount Sinai

Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.

Sessions:

• PMWC 2024 Award Ceremony
  Pioneer Honoree: Atul Butte, UCSF
  
• Fostering Collaboration: Strategies to Enhance Data Sharing in Medical Research (PANEL)
  Chair: Craig Eagle, Guardant Health
  - Paul Boutros, UCLA
  - Atul Butte, UCSF
  - George Sledge, Caris Life Sciences
  - Erica Galvez, Manifest MedEx
• Regulatory Challenges in Collecting and Using Race and Ethnicity Data in Real-World Evidence
  Chair: Susan Winkler, Reagan-Udall Center
  
• Multi-Modal Datasets & RWE/D: Pioneering Tools for Accelerated Biomedical Research
  Chair: TBA
  
• Data Privacy and Security in RWE/D
  Chair: Deven McGraw, Invitae
  - Christopher Boone, AbbVie
  - Susan Stayn, Stanford
  - Alexa Berk King, CVS
  
• Accelerating Drug Development Approvals Using RWE/D (PANEL)
  Chair: Maria Karasarides, BMS
  - Leo Russo, Pfizer
  - Eric Schadt, Ethos AI
  - Ashley Brenton, Optum